Disease Modelling & Screening Platform
|
|
|
|
|
|
|
The Disease Modelling & Screening Platform (DMSP) provides infrastructure and services related to early drug discovery. This platform is a collaboration between the LCSB and the Luxembourg Institute of Health (LIH). It combines the cellular disease modelling expertise of both institutions with early drug discovery technology. The High‐Throughput Screening / High Content Screening equipment is located at the LCSB (BT2). |
This state-of-the-art platform facilitates the translation of scientific discoveries into tangible drug candidates. It acts as an interface between fundamental biomedical research and high standard drug discovery to:
- help researchers develop screenings based on their biological findings
- perform screenings with DMSP compounds or with the researchers’ library
- develop new cellular disease models for phenotypic screenings
- offer phenotypic screenings in established patient-derived cellular models
To know more, go to the dedicated website >>
Contact information
Dr Meritxell Bao Cutrona
Head of the Disease Modeling & Screening Platform
Email: Meritxell.Cutrona@lih.lu
Visiting Address:
BioTech II - Luxembourg Centre for Systems Biomedicine
Campus Belval, Université du Luxembourg
6, Avenue du Swing - L-4367 Belvaux
Location on Google Maps ⇗
| Platform manager |
|
|
|
|
|
|
| Dr. Meritxell Bao Cutrona (LIH) |
|
|
|
|
|
|
| Researchers |
|
|
|
|
|
|
|
|
|
|
| Technicians |
|
|
|
|
|
|
|
|
|
Visiting researchers:
Dr. Bruno Dos Santos Rodrigues (LIH)
Tatiana Michel (LIH)
Arkadiusz Rybicki (LIH)
